Pediatr. praxi. 2013;14(4):225-227

What is new in pediatric diabetes

doc.MUDr.Zdeněk Šumník, Ph.D.
Pediatrická klinika UK 2. LF a FN v Motole, Praha

The aim of this article is to present the overview about basic developments in pediatric diabetes in several years. The paper included

following topics: 1. Changes in epidemiological characteristics in childhood diabetes, 2. Prediction of type 1 diabetes (T1D), 3. Possibilities

of prevention T1D, 4. Update on diagnostics of diabetes, 5. New criteria of diabetes control in children, 6. Differential diagnostics

of diabetes, and 7. Diabetes technology news.

Keywords: type 1 diabetes, epidemiology, diagnostic criteria, diabetes control, prediction, closed-loop system

Published: August 29, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šumník Z. What is new in pediatric diabetes. Pediatr. praxi. 2013;14(4):225-227.
Download citation

References

  1. Cinek O, Kulich M, Šumník Z. The incidence of type 1 diabetes in young Czech children stopped rising. Pediatr Diabetes 2012; 13(7): 559-563. Go to original source... Go to PubMed...
  2. Patterson CC, Gyürüs E, Rosenbauer J, Cinek O, et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012; 55(8): 2142-2147. Go to original source... Go to PubMed...
  3. Gyurus EK, Patterson C, Soltesz G. Hungarian Childhood Diabetes Epidemiology Group. Twenty-one years of prospective incidence of childhood type 1 diabetes in Hungary - the rising trend continues (or peaks and highlands). Pediatr Diabetes 2012; 13(1): 21-25. Go to original source... Go to PubMed...
  4. Andersson C, Larsson K, Vaziri-Sani F, et al. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 2011; 44(5): 394-405. Go to original source... Go to PubMed...
  5. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366(5): 433-442. Go to original source... Go to PubMed...
  6. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378(9790): 487-497. Go to original source... Go to PubMed...
  7. Simpson M, Brady H, Yin X, et al. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 2011; 54(11): 2779-2788. Go to original source... Go to PubMed...
  8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl. 1): S62-S69. Go to original source... Go to PubMed...
  9. Česká diabetologická společnost. Doporučený postup péče o nemocné s diabetem 1. typu. DMEV 2012; 15(1): 8-11.
  10. Revers M, Pihoker C, Donaghue K, et al. Assessment and monitoring of glycemic control. Pediatr Diabetes 2009(Suppl 12); 10: 71-81. Go to original source... Go to PubMed...
  11. Průhová S, Dušátková P, Neumann D, et al. Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is It Time to Change the Diagnostic Criteria for MODY? Diabetes Care 2013; Apr 22 [Epub ahead of print]. Go to original source... Go to PubMed...
  12. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368(9): 824-833. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.